Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor-Specific Mutant Antigen (TSA)
- Target
- TSA
- Molecular classification
- Protein, Peptide
01
Overview
A tumor-specific mutant antigen, often referred to as a tumor-specific antigen (TSA) or neoantigen, is a molecule—typically a protein or peptide—that arises from genetic mutations unique to cancer cells. These antigens are not present in normal, healthy cells and are generated by somatic mutations in the DNA of tumor cells. As such, they can be recognized by the immune system as "non-self," making them attractive targets for cancer immunotherapy.
- Other names
- Tumor-Specific AntigenNeoantigenMutant Tumor Antigen
02
Mechanism of action
Targeted by personalized cancer vaccines and adoptive T-cell therapies designed to recognize specific mutant peptide-MHC complexes on tumors.
03
Biological functions
Immune responseAntigen presentationT-cell activationTumor cell recognition
04
Disease associations
Cancer
05
Safety considerations
Off-target effects (minimized due to tumor specificity)Autoimmunity (low risk due to tumor specificity)Individualized identification required (challenging and costly)Limited 'public' neoantigens shared across patients
06
Biomarkers
Mutated TP53 (e.g., R175H)Mutated KRAS (e.g., G12D)Mutated BRAF (e.g., V600E)Patient-specific neoantigens identified through genomic sequencing
Beyond the preview
Go deeper on Tumor-Specific Mutant Antigen (TSA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor-Specific Mutant Antigen (TSA).